Arrowhead Corp (ARWR) - Long-Term Debt to Capital Coefficient

Arrowhead Pharmaceuticals (ARWR) generates revenue through royalties and licensing fees from global pharma behemoths for access to its unique technologies. The company invests heavily in R&D to create systems for the targeted suppression of pathological genes. This price chart on the GURU.Markets platform, where the metric stands at 2.88, reflects the dynamics of a business developing revolutionary liver treatments by "switching off" diseases at the genetic level.

Arrowhead Pharma (ARWR): Long-Term Debt to Equity from 07/04/2022 to 10/30/2026

Comprehensive metric breakdowns and analytics for Arrowhead Pharmaceuticals (ARWR)

- stock price and consensus target price:

Quote Chart Arrowhead Pharma|ARWR - Analyst Consensus Forecast

- market capitalization indicators:

Market Value Arrowhead Pharmaceuticals, Inc.|ARWR - Enterprise Value

- balance sheet net asset value indicators:

Book Value per Share Arrowhead Pharmaceuticals|ARWR - Company Book Value|Market Value to Book Value arrowheadpharma.com|ARWR - Aggregate Company Assets

- debt and solvency information:

Total Debt to Equity Ratio Arrowhead Pharmaceuticals|ARWR - Long-Term Debt to Capital|Short-Term Debt to Capital arrowheadpharma.com|ARWR - Company Total Debt|Debt to Net Assets Ratio Arrowhead Pharmaceuticals, Inc.|ARWR - Company Long-Term Debt|Company Short-Term Debt Arrowhead Pharmaceuticals|Interim Coverage Ratio arrowheadpharma.com

- net income and valuation ratios data:

ARWR - Net Income

General company analysis:Arrowhead Pharma - ARWR

Signature product of Arrowhead Pharmaceuticals

Leveraging an organic growth strategy and licensing agreements with pharma behemoths, the current long-term debt-to-equity ratio reflects the financial stability of Arrowhead Pharmaceuticals (ARWR). This metric compares obligations with maturities exceeding one year against shareholders' equity, allowing investors to assess the degree of leverage: low values confirm a conservative approach to funding R&D without the risk of excessive credit burden.

Analysis of competing companies

Mirum Pharmaceuticals, Inc. - Long-Term Liabilities to Equity|Long-Term Debt to Capital DVAX|ABUS (Tekmira Pharmaceuticals) - Long-Term Debt to Capital Coefficient|Long-Term Debt to Capital IVA (Inventiva S.A.)|Long-Term Debt to Capital gyretx.com GYRE|ASMB - Long-Term Debt to Equity|Long-Term Debt to Capital Coefficient GALT (Galectin Therapeutics)|genfit.com (GNFT) - Long-Term Debt to Equity|Long-Term Debt to Equity Ratio DURECT|ALGS (Aligos Therapeutics Inc.) - Long-Term Debt to Capital|Long-Term Debt to Capital BioVie Pharma|Long-Term Debt to Equity Ratio GLMD (Galmed Pharmaceuticals)|NDRA (ENDRA Life Sciences Inc) - Long-Term Debt to Capital Coefficient|Long-Term Debt to Equity Hepion Pharmaceuticals, Inc. HEPA